Compugen
Manufacturing · Israel · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Azrieli Center Building D 26 Harokmim St...Phone Number
+972 37658585Website
www.cgen.comRevenue
$42.7 MillionStock Symbol
CGENIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Compugen
Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable, predictive computational discovery platforms to identify novel drug targets and develop therapeutics in the field of cancer immunotherapy.Explore more
Compugen Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Compugen your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Compugen had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Compugen
Earning: See what the market has to say on Compugen recently announced quarterly report
Compugen, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Compugen is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Compugen launches new products
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Compugen has new funding data
Check if Compugen has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at Compugen
Find 2 more new buyers
Company Profile Activity
Activity Insights
Compugen is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Compugen is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Compugen.
Compugen financials insights
Gather financial insights about Compugen, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Stock Offering
$51M
2021
Stock Offering
$20M
Compugen Tech Stack
A closer look at the technologies used by Compugen
See more technologies
Most Recent Scoops
Person-Based
Award
Person-Based
Medical Research, Clinical Operations
Project
Compugen has designed the MAIA study as an adaptive trial, with plans to explore combination arms including COM701 with Bevacizumab and antibody-drug conjugates (ADCs), as well as potential expansion into earlier or later lines of ovarian cancer and additional indications.
Project
Compugen is conducting the MAIA study to evaluate COM701 monotherapy in platinum-sensitive ovarian cancer patients in the second and third line, with an interim analysis including progression-free survival data expected by Q1 2027.
Medical Research, Clinical Operations
Project
Medical Research, Pharmaceuticals
Compugen News & Media
Compugen to Present Phase 1 MAIA-Ovarian Trial-in-Progress Poster at ESMO Gynaecological Cancers Congress 2026
HOLON, Israel, June 11, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational drug target discovery powered by AI/ML, today announced that it will present a trial-in-progress poster on the...Compugen to Participate in Jones Trading Fireside Chat Series with Leaders in AI/ML-based Drug Development
HOLON, Israel, June 8, 2026 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI/ML, today announced that management will participate in Jones Trading's Mapping the Path from...Compugen Ltd. (CGEN) Q1 2026 Earnings Call Transcript
Compugen Ltd. (CGEN) Q1 2026 Earnings Call May 18, 2026 8:30 AM EDTCompany ParticipantsLindsey TrickettEran Ophir - CEO, President & DirectorDavid...Compugen Q1 Earnings Call Highlights
Compugen (NASDAQ:CGEN) said it remains on track to report interim progression-free survival data in the first quarter of 2027 from its MAIA-ovarian study, as the clinical-stage immuno-oncology company outlined first-quarter 2026 results and updates across its internal and partnered programs. On the
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding Compugen
Sign Up For FreeTo access detailed company insights
Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable, predictive computational discovery platforms to identify novel drug targets and develop therapeutics in the field of cancer immunotherapy.... Read More
